13F reference period
Q3 2026
Security Snapshot
Theriva Biologics, Inc. - Common stock (TOVX) Institutional Ownership
CUSIP: 87164U508
13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026
Institutions Reporting
11
Shares (Excl. Options)
1.22M
Full value: 1,223,511 · shares · 30 Sep 2026Price
$0.22
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common stock
- Symbol
- TOVX on NYSE
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 1,223,511
- Total 13F value
- $275,419
- Portfolio coverage rank
- 0%
- Share change
- +66,856
- Value change
- +$15,173
- Number of holders
- 11
- Shares outstanding
- 9,600,143
- SEC-reported price per share
- $0.22
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- TOVX - Theriva Biologics, Inc. - Common stock is tracked under CUSIP 87164U508.
- 11 institutions reported positions in Q3 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 24 to 11 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$495.53K
Full value: $495,531 · USD · 30 Jun 2026.$275.42K
Full value: $275,419 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 11 institutions filings for Q3 2026.
Security key
87164U508
13F reference period
Q3 2026
13F holders
11
13D/G owners
3
CIK / CUSIP context first
Open Q3 2026 holders
TOVX full holder history
Theriva Biologics, Inc. SEC filings
Theriva Biologics, Inc. company facts
Theriva Biologics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 87164U508:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
TOVX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Matthew Gryga Irrevocable Trust | 7.7% | $300,046 | 739,211 | Jeffrey Matthew Gryga Irrevocable Trust | 24 Oct 2025 | |||
| Empery Asset Management, LP | 5% | -50% | $201,636 | -$179,638 | 504,091 | -47% | Empery Asset Management, LP | 30 Sep 2025 |
| CVI Investments, Inc. | 4.9% | $206,052 | 146,136 | CVI Investments, Inc. | 31 Dec 2024 |
As of 30 Sep 2026,
11
institutional investors reported holding
shares of
Theriva Biologics, Inc. - Common stock (TOVX).
This represents
13%
of the company’s total
outstanding shares.
1.22M
Full value: 1,223,511 · shares · 30 Sep 20269.6M
Full value: 9,600,143 · shares · Stored outstanding share count13F concentration
Top 11 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
13%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | 486,179 | 0% | 0% | $109,390 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.1% | 299,138 | +1.7% | 0% | $67,305 |
| VANGUARD FIDUCIARY TRUST CO | 2.5% | 241,780 | 0% | 0% | $54,401 |
| RENAISSANCE TECHNOLOGIES LLC | 1.1% | 109,500 | +72% | 0% | $24,638 |
| StoneX Group Inc. | 0.33% | 32,106 | 0% | $7,354 | |
| MORGAN STANLEY | 0.21% | 20,299 | 0% | 0% | $4,567 |
| Ground Swell Capital, LLC | 0.19% | 18,410 | -48% | 0.01% | $4,142 |
| SCHWARZ DYGOS WHEELER INVESTMENT ADVISORS LLC | 0.16% | 15,000 | 0% | 0% | $3,375 |
| SBI Securities Co., Ltd. | 0.01% | 1,083 | +203% | 0% | $244 |
| IFP Advisors, Inc | 0% | 11 | 0% | 0% | $2 |
| NFSG Corp | 0% | 5 | 0% | 0% | $1 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Headline period
Q3 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,223,511 | $275,419 | +$15,173 | $0.22 | 11 |
| 2026 Q2 | 1,980,374 | $495,531 | +$4,553 | $0.25 | 24 |
| 2026 Q1 | 1,965,271 | $385,351 | +$95,191 | $0.20 | 19 |
| 2025 Q4 | 1,295,504 | $272,379 | +$158,821 | $0.21 | 20 |
| 2025 Q3 | 437,052 | $177,030 | +$57,424 | $0.41 | 18 |
| 2025 Q2 | 291,012 | $126,275 | +$38,331 | $0.43 | 15 |
| 2025 Q1 | 190,681 | $209,751 | +$165,878 | $1.10 | 10 |
| 2024 Q4 | 34,470 | $60,323 | -$627,703 | $1.75 | 9 |
| 2024 Q3 | 491,424 | $677,871 | +$471,525 | $1.38 | 16 |